secwatch.observer — SEC 8-K summary
======================================

Issuer:     Werewolf Therapeutics, Inc. (HOWL)
CIK:        0001785530
Form:       8-K
Filed at:   2025-03-11T23:59:59+00:00
Accession:  0001785530-25-000006
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Werewolf Therapeutics reports Q4 2024 net loss of $20.4M; cash runway through Q2 2026
--------------------------------------------------------------------------------

- Cash and cash equivalents $111.0M at Dec 31, 2024; sufficient to fund operations through Q2 2026.
- Net loss $20.4M in Q4 2024 vs $12.0M in Q4 2023; full year net loss $70.5M vs $37.4M.
- Collaboration revenue $0 in Q4 2024 as Jazz obligation completed; full year $1.9M vs $19.9M.
- WTX-124 monotherapy melanoma expansion arm expected fully enrolled H1 2025; combination arm by end of 2025.
- Plan to meet with FDA in H2 2025 for registrational pathways; interim data expected Q4 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1785530/000178553025000006/0001785530-25-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1785530/000178553025000006/howl-20250311.htm
  HTML page:      https://secwatch.observer/filing/0001785530-25-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer